Search research articles
Contact Us
Filters
Showing results (111-120 of 130) with videos related to
Page
of 13
Sort By:
JCO Precision Oncology
|
August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Philippe L Bedard, Shuli Li, Kari B Wisinski, et al.
The Prostate
|
May 6, 2021
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer
Victoria Wang, Milan S Geybels, Kristina M Jordahl, et al.
Blood
|
August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
Xin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Amy S Clark, Fangxin Hong, Richard S Finn, et al.
JCO Precision Oncology
|
February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Mohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Journal of the National Cancer Institute
|
March 17, 2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Lari Wenzel, Kathryn Osann, Chelsea McKinney, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 130) with videos related to
Sort By:
Page
of 13
JCO Precision Oncology
|
August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Philippe L Bedard, Shuli Li, Kari B Wisinski, et al.
The Prostate
|
May 6, 2021
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer
Victoria Wang, Milan S Geybels, Kristina M Jordahl, et al.
Blood
|
August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
Xin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 28, 2023
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Amy S Clark, Fangxin Hong, Richard S Finn, et al.
JCO Precision Oncology
|
February 6, 2025
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Mohamed A Gouda, Zihan Wei, Jordi Rodon, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Journal of the National Cancer Institute
|
March 17, 2021
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Lari Wenzel, Kathryn Osann, Chelsea McKinney, et al.
Page
of 13